Thus, via a data-driven and bottom-up modelling approach [51], the in silico model developed in this study can be built upon to simulate how BRAF-MEK-ERK inhibition affects not only intracellular ERK activity but also the progression of drug resistance in melanoma tumours. Here, MAPK1 is linked to melanoma.